To direct the Secretary of Defense to submit to Congress a report on emerging investigational treatment options for treatment-resistant post-traumatic stress disorder in veterans, members of the Armed Forces, and members transitioning to civilian life, and for other purposes.
Summary
Rep. Hamadeh introduced HR9547 directing the Secretary of Defense to report on emerging investigational treatments for treatment-resistant PTSD in veterans and service members. The bill is early stage, referred to committee, with no funding authorized or specific mandate beyond a report. No direct financial impact on any public company is identifiable.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9547 is a reporting bill with zero authorized or appropriated funding — no near-term financial impact on any company.
- 2.No public company is directly affected; the causal chain gate is not met for any ticker.
- 3.Legislative likelihood is low: early stage, junior sponsor, no companion bill.
Market Implications
No market implications. The bill does not change any company's revenue, costs, or competitive position. Investors should focus on bills with measurable funding or regulatory impact.
Full Analysis
On 2026-06-30, Rep. Abraham Hamadeh (R-AZ-8) introduced HR9547 in the 119th Congress. The bill directs the Secretary of Defense to submit a report to Congress on emerging investigational treatment options for treatment-resistant PTSD in veterans, current Armed Forces members, and those transitioning to civilian life. The bill was referred to the House Committee on Armed Services and has three cosponsors. It is in early legislative stage with no further action taken.
There is no funding authorized or appropriated in this bill. It is purely a reporting requirement — a study mandate — with no procurement, contract, grant, or market mechanism. The report would summarize existing research and treatment options but creates no obligation for the Department of Defense to purchase or adopt any specific therapy. As such, there is no direct revenue stream for any public company.
No convergence data is provided in the enrichment data, and no related bills, procurement, or executive actions are available for cross-reference. The bill stands alone as a procedural inquiry.
Under RULE 25 (Veterans/VA Guardrail), even though the bill involves the military, its subject is a medical treatment report, not defense procurement. The affected sectors are Healthcare (for the treatment research) and Defense (since the reporting entity is DoD). However, no tickers meet the causal chain gate — no public company's revenue or business is directly affected by a reporting requirement. Sponsorship by a junior member and lack of committee leadership further suggest low momentum.
The legislative path is long: committee markup, House vote, Senate companion, conference, and presidential action. Given an early-stage procedural bill with no funding, remaining steps are extensive and passage uncertain.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
SLS FEDERAL SERVICES LLC: $1.3B Department of Homeland Security Contract
RAUMA MARINE CONSTRUCTIONS OY: $1.1B Department of Homeland Security Contract
SPENCER CONSTRUCTION LLC: $1.1B Department of Homeland Security Contract
PANTEXAS DETERRENCE, LLC: $3.5B Department of Energy Contract
FISHER SAND & GRAVEL CO: $2.8B Department of Homeland Security Contract
SOUTHWEST VALLEY CONSTRUCTORS CO: $1.7B Department of Homeland Security Contract
RAUMA MARINE CONSTRUCTIONS OY: $1.1B Department of Homeland Security Contract
PANTEXAS DETERRENCE, LLC: $3.5B Department of Energy Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Establishing an America First Arms Transfer Strategy
This executive order directs the Secretary of War, along with the Secretaries of State and Commerce, to create an 'America First Arms Transfer Strategy' that prioritizes foreign arms sales to boost U.S. defense industrial base capacity, streamline export processes, and enhance production of key weapons systems. It mandates a sales catalog of prioritized platforms within 120 days, forms a task force to improve coordination, and reforms congressional notification procedures for arms transfers.
Ushering in the Next Frontier of Quantum Innovation
This executive order updates the National Quantum Strategy and establishes a national effort (QC-ADDS) to develop a quantum computer for scientific discovery, with deployment at a Department of Energy facility. It directs multiple agencies to prioritize quantum sensing, networking, and supply chain initiatives, and mandates plans for commercial readiness and national security applications.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →